Search research articles
Contact Us
Filters
Showing results (101-110 of 133) with videos related to
Page
of 14
Sort By:
Ejhaem
|
April 18, 2024
Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project
Briony Shaw, Eliza Chung, Cameron Wellard, et al.
Occupational and Environmental Medicine
|
September 18, 2023
Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case-control study
Michael K Odutola, Marina T van Leeuwen, Fiona J Bruinsma, et al.
Blood
|
June 13, 2012
E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis
Kamil Wolyniec, Jake Shortt, Elisa de Stanchina, et al.
Blood
|
February 23, 2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
Constantine S Tam, John N Allan, Tanya Siddiqi, et al.
Haematologica
|
March 7, 2024
Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study
Allison Barraclough, Shivam Agrawal, Dipti Talaulikar, et al.
Frontiers in Nutrition
|
January 23, 2023
Dietary intake of animal-based products and likelihood of follicular lymphoma and survival: A population-based family case-control study
Michael K Odutola, Marina T van Leeuwen, Julie K Bassett, et al.
European Journal of Haematology
|
December 20, 2022
Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry
James Nguyen, Cameron Wellard, Eliza Chung, et al.
Blood Advances
|
August 19, 2025
Zanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies
Constantine S Tam, Mary Ann Anderson, Martin Simkovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
William G Wierda, John N Allan, Tanya Siddiqi, et al.
The New England Journal of Medicine
|
January 10, 2014
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
Valentin Goede, Kirsten Fischer, Raymonde Busch, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 133) with videos related to
Sort By:
Page
of 14
Ejhaem
|
April 18, 2024
Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project
Briony Shaw, Eliza Chung, Cameron Wellard, et al.
Occupational and Environmental Medicine
|
September 18, 2023
Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case-control study
Michael K Odutola, Marina T van Leeuwen, Fiona J Bruinsma, et al.
Blood
|
June 13, 2012
E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis
Kamil Wolyniec, Jake Shortt, Elisa de Stanchina, et al.
Blood
|
February 23, 2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
Constantine S Tam, John N Allan, Tanya Siddiqi, et al.
Haematologica
|
March 7, 2024
Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study
Allison Barraclough, Shivam Agrawal, Dipti Talaulikar, et al.
Frontiers in Nutrition
|
January 23, 2023
Dietary intake of animal-based products and likelihood of follicular lymphoma and survival: A population-based family case-control study
Michael K Odutola, Marina T van Leeuwen, Julie K Bassett, et al.
European Journal of Haematology
|
December 20, 2022
Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry
James Nguyen, Cameron Wellard, Eliza Chung, et al.
Blood Advances
|
August 19, 2025
Zanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies
Constantine S Tam, Mary Ann Anderson, Martin Simkovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
William G Wierda, John N Allan, Tanya Siddiqi, et al.
The New England Journal of Medicine
|
January 10, 2014
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
Valentin Goede, Kirsten Fischer, Raymonde Busch, et al.
Page
of 14